首页> 外文OA文献 >Efficacy of two vaccine formulations against contagious bovine pleuropneumonia (CBPP) in Kenyan indigenous cattle
【2h】

Efficacy of two vaccine formulations against contagious bovine pleuropneumonia (CBPP) in Kenyan indigenous cattle

机译:两种疫苗制剂对肯尼亚本土牛传染性牛胸膜肺炎(CBpp)的疗效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A live, attenuated vaccine is currently the only viable option to control of CBPP in Africa. It has been suggested that simple modifications to current vaccines and protocols might improve efficacy in the field. In this report we compared the current vaccine formulation with a buffered preparation that maintains Mycoplasma viability at ambient temperature for a longer time. Groups of animals were vaccinated with the two formulations and compared with non vaccinated groups. Half of the animals in each group were challenged 3 months post vaccination, the other half after 16 months. Protection levels were measured using the pathology index, calculated from post mortem scores of lesions from animals killed during the course of clinical disease. In the challenge at 3 months post vaccination, the protection levels were 52% and 77% for the modified and current vaccine preparations, respectively. At 16 months post vaccination, the protection levels were 56% and 62% for the modified and current vaccine preparations, respectively. These findings indicate that there are no differences in protection levels between the two vaccines. Because of its longer half life after reconstitution, the modified vaccine might be preferred in field situations where the reconstituted vaccine is likely not to be administered immediately.
机译:减毒活疫苗目前是控制非洲CBPP的唯一可行选择。已经提出,对当前疫苗和方案的简单修改可以提高该领域的功效。在本报告中,我们将当前的疫苗制剂与在室温下能更长久保持支原体活力的缓冲制剂进行了比较。用两种制剂给动物组接种疫苗,并与未接种的组进行比较。接种疫苗后3个月,每组中的一半动物受到攻击,而16个月后另一半。使用病理指数来测量保护水平,该病理指数是根据在临床疾病过程中被杀死的动物的病灶的事后评分计算得出的。在接种疫苗后3个月的攻击中,改良和当前疫苗制剂的保护水平分别为52%和77%。接种疫苗后16个月,改良和当前疫苗制剂的保护水平分别为56%和62%。这些发现表明两种疫苗之间的保护水平没有差异。由于其重组后的半衰期较长,因此在可能无法立即施用重组疫苗的现场情况下,可能会首选改良疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号